This episode regards a United States Court of Appeals for the Federal Circuit opinion, dated October 30, 2025, concerning a patent dispute between Merck Serono S.A. and Hopewell Pharma Ventures, Inc. The case involves Merck's appeal of two consolidated inter partes reviews (IPRs) before the Patent Trial and Appeal Board (Board), which had found certain claims of two Merck patents related to an oral cladribine regimen for treating multiple sclerosis (MS) unpatentable as obvious. The primary le...
All content for Condensed IP is the property of Randy Noranbrock and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
This episode regards a United States Court of Appeals for the Federal Circuit opinion, dated October 30, 2025, concerning a patent dispute between Merck Serono S.A. and Hopewell Pharma Ventures, Inc. The case involves Merck's appeal of two consolidated inter partes reviews (IPRs) before the Patent Trial and Appeal Board (Board), which had found certain claims of two Merck patents related to an oral cladribine regimen for treating multiple sclerosis (MS) unpatentable as obvious. The primary le...
Bayer v. Mylan (Fed. Cir., September 23, 2025) 2023-2434
Condensed IP
10 minutes
1 month ago
Bayer v. Mylan (Fed. Cir., September 23, 2025) 2023-2434
This opinion from the United States Court of Appeals for the Federal Circuit concerns a patent infringement appeal case, Bayer Pharma Aktiengesellschaft v. Mylan Pharmaceuticals Inc. The appeal concerns the Patent Trial and Appeal Board's (PTAB) final written decision holding claims of Bayer's U.S. Patent No. 10,828,310, which describes methods using rivaroxaban and aspirin to reduce cardiovascular risk, unpatentable. The Court affirms-in-part and vacates-in-part the PTAB's decision, specific...
Condensed IP
This episode regards a United States Court of Appeals for the Federal Circuit opinion, dated October 30, 2025, concerning a patent dispute between Merck Serono S.A. and Hopewell Pharma Ventures, Inc. The case involves Merck's appeal of two consolidated inter partes reviews (IPRs) before the Patent Trial and Appeal Board (Board), which had found certain claims of two Merck patents related to an oral cladribine regimen for treating multiple sclerosis (MS) unpatentable as obvious. The primary le...
